CN Healthy Food Tech Group Corp.UCFI

CN Healthy Food Tech Group Corp., a US-listed company that sells sprayable skin essential oil blending Traditional Chinese Medicine with modern technology, filed its latest quarterly numbers with the SEC on 21 July 2026 via an 8-K, pulling forward the financial picture from the 10-Q for the period ending 31 March 2026. Revenue came in at $5.8 million, operating income was $730,616, yet the net loss attributable to the parent reached $308,997. The company carries $29.7 million in cash against $19.2 million in liabilities, with stockholders' equity of $19.9 million. The cash pile is a legacy of the SPAC merger, not of organic product sales.

The business describes itself as integrating research, development, production, and sales of high-end technological bio-health foods, with its lead product a sprayable skin essential oil. The 10-K filed in March 2026 and the November 2025 10-Q both stress the company's ability to meet expectations for its products and services, yet the actual operating figures show a company still in early revenue mode. R&D expense of $38,370 in the March 2026 quarter is modest for a business claiming a high-tech bio-health mandate. Inventory declined by $286,346 to $850,946, which could reflect either tighter supply management or softer demand.

Cash flow tells a harder story. Net cash used in operating activities was $3.6 million for the quarter, while capital expenditures were just $1,554. The company is not reinvesting in physical assets at a scale that matches its platform language. The weighted average diluted share count of 52.2 million shares produced a diluted EPS of negative one cent. The share count and the cash balance are the two numbers that dominate the file, far more than any product metric.

The company's filing history on SEC EDGAR shows a string of promissory notes from September 2025 issued to SPAC sponsors, carrying 15% default interest and daily cash penalties for late share delivery. These instruments are a direct window into the financial structure that delivered the public listing. The 8-K from 21 July 2026 carried a press release whose content was not parsed in the source rail, leaving the precise nature of the announcement unknown. The absence of a full earnings release with forward guidance means the market is trading on a thin set of backward-looking data.

What would deepen this file is a clear breakdown of product revenue by channel, customer concentration, gross margin, and a management discussion that explains how the $29.7 million cash balance will be deployed before it gets consumed by operating losses and SPAC-related obligations. Until then, the file is a study in the gap between a polished Traditional Chinese Medicine tech narrative and the plain numbers of a small, cash-burning, post-SPAC entity.